Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Backgrounds And Aims: CD56 immunostain is used as an adjunct to aid in the preoperative diagnosis of biliary atresia (BA) by liver biopsy. We aimed to study the expression of CD56 in different pediatric cholestatic diseases thereby evaluating its utility in the diagnosis of BA.
Methods: We performed immunohistochemistry for CD56 on 35 cases of pediatric cholestatic diseases and five age-matched controls. CD56 expression was assessed by a multiplication score (percentage positivity x intensity) in the biliary epithelium.
Results: The multiplication score between BA and choledochal cyst was not significantly different. High scores were also encountered in other cholestatic disorders. The score showed a significant negative association with serum albumin and a significant positive correlation with the serum ALT level. Very significant positive correlation between the score and portal fibrosis was obtained.
Conclusion: CD56 expression is an infidel marker for the histological diagnosis of BA and rather provides a clue to the disease status in pediatric cholestatic diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15513815.2020.1765917 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on "The 'ABC' of genetics in cholestatic liver diseases.".
Dig Liver Dis
September 2025
Pathology Unit, Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Electronic address:
Macrophages drive a fibrogenic gene program of periductal fibroblasts in pediatric primary sclerosing cholangitis.
bioRxiv
August 2025
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229.
Primary sclerosing cholangitis (PSC) is an autoimmune, cholestatic liver disease characterized by inflammation and fibrosis surrounding bile ducts. The cellular crosstalk driving periductal fibrosis remains poorly defined. This study applied a multi-omics approach integrating MERSCOPE spatial transcriptomics, bulk RNA-seq, and SomaScan proteomics to characterize fibrotic periductal regions and their cell-cell communications.
View Article and Find Full Text PDFEfficacy, Effectiveness, and Safety of Phenobarbital in the Treatment of Cholestasis and as a Premedication to Improve Diagnostic Accuracy of Hepatobiliary Scintigraphy: A Systematic Review.
Acta Med Philipp
July 2025
Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila.
Objective: Phenobarbital is an inductor of microsomal hepatic enzyme and used as choleretic for cholestatic liver disease to enhance bile flow. It is also used as a premedication for hepatobiliary scintigraphy (HIDA) scan to improve diagnostic accuracy for an obstructive liver disease. We reviewed the available literature on the use of Phenobarbital for treatment of cholestasis and its utility as a premedication for HIDA scan.
View Article and Find Full Text PDFRepeated cholangiogram under pressure reveals rare type I-b1-β biliary atresia: A case report with diagnostic and surgical implications.
Int J Surg Case Rep
August 2025
Department of Pediatric Surgery, Ehime Prefectural Central Hospital, Ehime, Japan. Electronic address:
Introduction: Biliary atresia (BA) is a progressive cholestatic disease in neonates and infants, and early diagnosis and treatment significantly impact prognosis. Definitive diagnosis is based on cholangiogram findings, classifying BA into three main types. Among its variants, type I-b1-β-where the common bile duct is blocked, the distal duct is fibrous, and the tiny intrahepatic ducts are underdeveloped-is particularly rare.
View Article and Find Full Text PDFIdiopathic cholestasis in adults: Genetics as another lens for liver pathologists.
Hum Pathol
August 2025
Departments of Internal Medicine (Digestive Diseases), Genetics and Pathology, Yale School of Medicine, New Haven, CT, USA. Electronic address:
Chronic liver disease (CLD) is a significant global health problem, responsible for approximately two million deaths annually. Despite extensive diagnostic evaluations, a proportion of patients with CLD remain undiagnosed, making the study and quantification of these cases challenging. Genetic testing has emerged as a critical diagnostic tool, identifying monogenic causes in a substantial portion of undiagnosed cases.
View Article and Find Full Text PDF